Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.
Date
2022-04-06ICR Author
Author
Dimou, P
Trivedi, S
Liousia, M
D'Souza, RR
Klampatsa, A
Type
Journal Article
Metadata
Show full item recordAbstract
Precision-cut tumor slices (PCTS) have recently emerged as important ex vivo human tumor models, offering the opportunity to study individual patient responses to targeted immunotherapies, including CAR-T cell therapies. In this review, an outline of different human tumor models available in laboratory settings is provided, with a focus on the unique characteristics of PCTS. Standard PCTS generation and maintenance procedures are outlined, followed by an in-depth overview of PCTS utilization in preclinical research aiming to better understand the unique functional characteristics of cytotoxic T cells within human tumors. Furthermore, recent studies using PCTS as an ex vivo model for predicting patient responses to immunotherapies and other targeted therapies against solid tumors are thoroughly presented. Finally, the advantages and limitations of the PCTS models are discussed. PCTS are expected to gain momentum and be fully utilized as a significant tool towards better patient stratification and personalized medicine.
Collections
Subject
CAR-T cells
PCTS
cytotoxic T cells
ex vivo models
immunotherapy
organotypic tumor slices
precision-cut tumor slices
solid tumors
Research team
Thor Onco Immuno Group
Language
eng
Date accepted
2022-04-01
License start date
2022-04-06
Citation
Antibodies, 2022, 11 (2), pp. 26 -
Publisher
MDPI